Back to search results

Phase 3 Study for Gastric/GEJ Adenocarcinoma

This study is for people with HER2-negative, previously untreated, unresectable (cannot be removed by surgery) or metastatic (spread to other parts of the body) gastric (stomach) or gastroesophageal junction (GEJ, where the esophagus meets the stomach) adenocarcinoma. It compares two treatment approaches: cadonilimab (an anti-PD-1/CTLA-4 antibody) combined with chemotherapy (CAPOX regimen) versus chemotherapy with or without nivolumab (an anti-PD-1 antibody). The main goal is to see if one treatment helps people live longer. You may be able to join if you are 18 or older and have a confirmed diagnosis of this type of cancer, without prior treatment for it. The study is currently unclear on its recruitment status.

Study design
This is a randomized, double-blind, multi-regional Phase 3 study aiming to enroll 900 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Overall survival will be measured for approximately up to 14 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07700979

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
Akeso
~900 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:CadonilimabCAPOX regimenNivolumabPlacebo

At a glance

Recruiting sites
0 of 25 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival (OS)
Measured over Approximately up to 14months

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Explore related trials

Gastroesophageal Junction AdenocarcinomaProgrammed Cell Death 1 Ligand 1

NCT07700979

Where you'd take part

This study runs at 25 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baylor Scott & White Health

    Dallas, Texasno site contact published

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Chinano site contact published

  • Dana Farber Cancer Institute

    Boston, Massachusettsno site contact published

  • Guangdong Provincial People's Hospital

    Guangzhou, Chinano site contact published

  • Henry Ford Health

    Detroit, Michiganno site contact published

  • Mayo Clinic

    Phoenix, Arizonano site contact published

  • MD Anderson Cancer Center

    Houston, Texasno site contact published

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jiafu Ji, MD · PRINCIPAL_INVESTIGATOR · Peking University Cancer Hospital, Beijing, Beijing 100142, China
  • Lin Shen, MD · PRINCIPAL_INVESTIGATOR · Peking University Cancer Hospital, Beijing, Beijing 100142, China
  • Markus Mohler, MD · PRINCIPAL_INVESTIGATOR · Johannes Gutenberg University Clinic, Germany

Who to contact

Zhifang Yao, MD
[email protected]
86-0760-89873999
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Overall survival (OS)Approximately up to 14months

    Time from randomization to death from any cause